Although we assessed at least 30% decline in eGFR as a valid surrogate end point for CKD progression,49,50 due to the low number of incident kidney failure requiring kidney replacement in this cohort, we were unable to examine the association of incident TNF inhibitor use with a tangible kidney outcome. This evidence concerns the gene TNF and chronic kidney disease.